Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | DAO | P14920 | 2/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RPA1 | P27694 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | TPMT | P51580 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6622235 | 0.96 | NOTUM (0.39) | NOTUMKDM4EGAAHPGDHSD17B10 | |
| SCHEMBL23758516 | 0.83 | ALDH1A1 (0.40) | NOTUMKDM4EGAAHPGDHSD17B10 | |
| SCHEMBL3728873 | 0.81 | CYP1A2 (0.40) | GAAALDH1A1L3MBTL1MAPK1MEN1 | |
| SCHEMBL4472003 | 0.79 | ALOX15 (0.48) | KDM4EGAAHPGDHSD17B10ALDH1A1 | |
| SCHEMBL17883332 | 0.79 | ALDH1A1 (0.38) | ALDH1A1MAPK1MAPTPOLB | |
| SCHEMBL3105456 | 0.77 | NOTUM (0.39) | NOTUMDAOHCAR2GPR17 | |
| SCHEMBL3060385 | 0.77 | KDM4E (0.39) | NOTUMKDM4EGAAHPGDHSD17B10 | |
| SCHEMBL31386913 | 0.77 | NOTUM (0.39) | NOTUMKDM4EGAAHPGDHSD17B10 | |
| SCHEMBL14157647 | 0.77 | GPR35 (0.41) | NOTUMKDM4EGAAHPGDHSD17B10 | |
| SCHEMBL15979650 | 0.77 | ALDH1A1 (0.41) | KDM4EGAAALDH1A1L3MBTL1GPR17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200261383-A1 | PHARMACEUTICAL COMPOSITIONS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2020-08-20 | — | — | US | claimed |
| EP-3664780-A1 | PHARMACEUTICAL COMPOSITIONS | Kalvista Pharmaceuticals Limited (GB) | 2020-06-17 | — | — | EP | claimed |
| EP-2729443-B3 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2020-02-12 | — | — | EP | claimed |
| US-10478409-B2 | Pharmaceutical compositions | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2019-11-19 | — | — | US | claimed |
| EP-2943181-B1 | PHARMACEUTICAL COMPOSITIONS | KALVISTA PHARMACEUTICALS LTD (GB) | 2019-04-10 | — | — | EP | claimed |
| US-20190070149-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2019-03-07 | — | — | US | claimed |
| WO-2019030540-A1 | PHARMACEUTICAL COMPOSITIONS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2019-02-14 | — | — | WO | claimed |
| US-20180021271-A1 | Pharmaceutical Compositions | KALVISTA PHARMACEUTICALS LTD (GB) | 2018-01-25 | — | — | US | claimed |
| US-9849100-B2 | Pharmaceutical compositions suitable for parenteral administration comprising aqueous suspensions of benzylamine derivatives having low solubilities | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2017-12-26 | — | — | US | claimed |
| EP-2948454-B1 | TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENT & IND RES AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGISTRATION OF SOCIETI (IN) | 2017-05-31 | — | — | EP | claimed |
| EP-1680124-A2 | BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS | Pfizer Products Incorporated (US) | 2006-07-19 | — | — | EP | claimed |
| US-6911458-B2 | Compounds | ASTRA ZENECA (SE) | 2005-06-28 | — | — | US | claimed |
| US-20050096375-A1 | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors | PFIZER INC. | 2005-05-05 | — | — | US | claimed |
| US-20050090494-A1 | Novel compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2005-04-28 | — | — | US | claimed |
| WO-2005037216-A2 | BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-04-28 | — | — | WO | claimed |
| JP-2004507461-A | — | — | 2004-03-11 | — | — | JP | claimed |
| CN-1476434-A | Novel compounds | — | 2004-02-18 | — | — | CN | claimed |
| US-20030162772-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2003-08-28 | — | — | US | claimed |
| EP-1299357-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2003-04-09 | — | — | EP | claimed |
| WO-2001098273-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-12-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190070149-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR1A | NOTUM 2411/4885KDM4E 2520/4885GAA 1403/4885 |
| US-20200261383-A1 | PHARMACEUTICAL COMPOSITIONS | ADCY9, PDE6D, PDE6G | NOTUM 1438/4885KDM4E 2993/4885GAA 1092/4885 |
| US-20050090494-A1 | Novel compounds | CHRM2, CHRM1, C1R | NOTUM 3275/4885KDM4E 1451/4885GAA 2229/4885 |
| US-20050096375-A1 | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors | SLC6A5, SLC1A5, SLC6A3 | NOTUM 2071/4885KDM4E 2032/4885GAA 1239/4885 |
| US-20180021271-A1 | Pharmaceutical Compositions | PDE6D, ABCC9, PDE6H | NOTUM 3945/4885KDM4E 3115/4885GAA 1810/4885 |
| US-20030162772-A1 | Novel compounds | RPS4X, RPS4Y1, MRPS18A | NOTUM 2579/4885KDM4E 1288/4885GAA 962/4885 |
| US-10478409-B2 | Pharmaceutical compositions | PDE6D, ABCC9, PDE6H | NOTUM 3945/4885KDM4E 3115/4885GAA 1810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.